GLP-2 (Tirzepatide) 20mg

Product Category

High-Potency Incretin Mimetics, Dual GIP/GLP-1 Receptor Agonists & Advanced Weight Loss Factors

Action on the Human Body

This high-dose GLP-2 (Tirzepatide) formulation is engineered to achieve deep receptor saturation across central and peripheral metabolic pathways. Operating as a dual agonist at both GIP and GLP-1 receptor sites, it amplifies insulin secretion dynamics in response to glucose fluctuations while protecting pancreatic islet cells from metabolic exhaustion. The 20mg dose provides robust saturation within the area postrema and hindbrain neural centers, thoroughly dampening hunger signals and delaying postprandial gastric clearance timelines. Peripheral pathways show accelerated mobilization of ectopic fat stores from the liver and skeletal muscle, forcing the body to transition into a highly efficient lipid-burning metabolic state while down-regulating systemic inflammatory factors associated with metabolic syndrome.

What to Expect if Consumed

Expect total control over daily caloric intake, a major reduction in stubborn visceral fat indices, optimized fasting glucose profiles, and enhanced long-term vascular and metabolic protective benefits.

Possible Therapy Combinations

Pairs perfectly with MOTS-C to supercharge mitochondrial fat oxidation during weight loss protocols, or combined with NAD+ to maintain high systemic cellular energy states during intensive calorie deficit cycles.

Molecular Formula & Chemical Composition

Molecular Formula: C225H348N48O68. Structure: High-Concentration 39-Amino Acid Acylated Incretin Analog. Purity: >99% Pure Lyophilized Mass.

WARNING: This peptide compound must be handled and utilized exclusively under very high, correct professional and qualified medical supervision. Misuse can lead to unintended biological variations.

Scientific References

1. Jastreboff, A. M., et al. (2022). ‘Tirzepatide Once Weekly for the Treatment of Obesity.’ New England Journal of Medicine.
2. Heise, T., et al. (2022). ‘Tirzepatide improves JAK/STAT and incretin-driven insulin sensitivity pathways: A mechanistic overview.’ Diabetes, Obesity and Metabolism.